(Q33399494)

26 July 2017

title

Gemcitabine in combination with vinorelbine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer (English)

1 reference

26 July 2017

main subject

metastatic breast cancer

1 reference

Ningning Dong

1

1 reference

26 July 2017

Mingyu Wang

2

1 reference

26 July 2017

Huiqing Li

3

1 reference

26 July 2017

Yongchun Cui

4

1 reference

26 July 2017

Qisen Guo

5

1 reference

26 July 2017

publication date

4 February 2012

1 reference

Cancer Chemotherapy and Pharmacology

26 July 2017

published in

1 reference

26 July 2017

volume

69

1 reference

26 July 2017

issue

5

1 reference

26 July 2017

page(s)

1315-1322

1 reference

26 July 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1830-1

Breast cancer in elderly women (≥ 80 years): variation in standard of care?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1830-1

Breast cancer in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1830-1

Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1830-1

A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1830-1

Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1830-1

Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1830-1

Phase II study of vinorelbine monotherapy in anthracycline and taxane pre-treated metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1830-1

Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1830-1

Vinorelbine as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: a cooperative study by the GEICAM group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1830-1

Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1830-1

Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1830-1

Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1830-1

Gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1830-1

Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1830-1

Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1830-1

Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1830-1

Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1830-1

Multidimensional geriatric evaluation in elderly cancer patients: a practical approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1830-1

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1830-1

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1830-1

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1830-1

First-line chemotherapy for metastatic breast cancer in patients ≥75 years: a retrospective single-centre analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1830-1

Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1830-1

10.1007/S00280-012-1830-1

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1048358833

0 references

1 reference